Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (DBCOND0130161)

Identifiers

Synonyms

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma / Advanced Adenocarcinoma of the Stomach, Including Gastroesophageal Junction

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Ramucirumab	An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.	Vascular endothelial growth factor receptor 2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04202601	Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer	Sintilimab	treatment	1 / 2	unknown_status
NCT02426034	A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer	No drug interventions	treatment	4	completed
NCT05585580	Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy	Albumin human Lenvatinib Paclitaxel Serplulimab	treatment	2	recruiting
NCT04435652	A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.	Paclitaxel	treatment	2 / 3	unknown_status